Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacira Pharmaceuticals reports record revenues and optimistic growth outlook

Pacira Pharmaceuticals had a strong financial performance in 2022, driven by EXPAREL's success and strategic initiatives. While facing challenges in pricing and reimbursement, the company is optimistic about future opportunities for growth through label expansions and market strategies.

Pacira Pharmaceuticals (PCRX) excels in Q1 2023 earnings call

Pacira Pharmaceuticals (PCRX) demonstrated robust financial performance, innovation in non-opioid pain management, and strategic market positioning in Q1 2023.
While facing challenges such as potential surgery trend moderation and pediatric market penetration, the company is leveraging opportunities in expanding EXPAREL use and regulatory advancements.
Overall, Pacira's focus on patient-centric solutions and market expansion initiatives position it well for continued growth and leadership in the pain management sector.

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q4 2020 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 6.10% and -0.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Q4 Earnings Beat Estimates

— Reports record full-year 2020 revenue of $429.6 million  —

Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results

PARSIPPANY, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial results before the open of the U.S. markets on Thursday, February 25, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report 2020 Financial Results on Thursday February 25, 2021

Cisco Systems

Lyft

Uber

VMware

Cameco

iRobot

MercadoLibre

Pacific Biosciences of California

Sumo Logic

With the trading day more than halfway over, the broad markets were trading sideways on Thursday.

Cisco, Lyft, Uber, VMware and More Thursday Afternoon Analyst Calls

EXPAREL average daily sales at 108% of the prior year for the month of January 2021 EXPAREL average daily sales at 108% of the prior year for the month of January 2021

Pacira BioSciences Reports Preliminary Net Product Sales of $36.0 Million for January 2021

Supports Development of Promising Gene Therapy Platform for Osteoarthritis Supports Development of Promising Gene Therapy Platform for Osteoarthritis

Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics

Pacira Pharmaceuticals saw an improvement in its IBD SmartSelect Composite Rating Tuesday, from 94 to 97. The post Composite Rating For Pacira Pharmaceuticals Rises To 97 appeared first on Investor's Business Daily.

Composite Rating For Pacira Pharmaceuticals Rises To 97

Amneal Pharmaceuticals

AMRX vs. PCRX: Which Stock Is the Better Value Option?

AMRX or PCRX: Which Is the Better Value Stock Right Now?

-- EXPAREL average daily sales at 109% of the prior year for the fourth quarter and 111% of the prior year for the month of December -- PARSIPPANY, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increase compared with net revenue of $421.0 million reported for 2019. The company's total revenues include net product sales of EXPAREL and iovera°, which were $125.3 million and $2.4 million for the fourth quarter of 2020 and $46.5 million and $0.6 million for the month of December 2020, respectively. EXPAREL average daily sales were 112 percent, 103 percent, and 111 percent of the prior year for the months of October, November, and December, respectively.

Pacira Reports Record Revenue for 2020 of $429.6 Million

PARSIPPANY, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference at 7:30 AM ET on Wednesday, January 13, 2021. Live audio of the virtual event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

-- EXPAREL average daily sales at 103% of the prior year for the month of November 2020 -- PARSIPPANY, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net product sales of EXPAREL® (bupivacaine liposome injectable suspension) and iovera° of $38.1 million and $0.8 million, respectively, for the month of November 2020.

Pacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020

PARSIPPANY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference at 11:30 AM ET on Tuesday, December 1, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the 2020 Piper Sandler 32nd Annual Virtual Healthcare Conference

The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.

Pacira (PCRX) Gets European Commission Approval for Exparel

--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachial plexus or femoral nerve block approved in Europe--

Pacira Receives European Commission Approval for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

-- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 -- -- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 --

Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020

PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at 2:05 PM GMT (9:05 AM ET) on Tuesday, November 17, 2020. Live audio of the virtual event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare Conference

Pacira's (PCRX) both bottom and the top line surpass estimates in Q3. Exparel sales rise year over year.

Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Beats Q3 Earnings and Revenue Estimates

-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET --

Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update

--The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning-- PARSIPPANY, N.J., and TAMPA, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NADSAQ: PCRX), the leading provider of non-opioid pain management options, today announced the grand opening of the Pacira Innovation and Training Center of Tampa (the PITT). Designed to advance clinician understanding of the latest local, regional and field block approaches for managing pain, the PITT will provide an unparalleled training environment for healthcare providers working to reduce or eliminate patient exposure to opioids.

Pacira Launches State-of-the-Art Training Center Dedicated to Advancing Best Practice Regional Approaches to Manage Acute Pain

Pacira BioSciences (PCRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Pacira BioSciences (PCRX) Enters Oversold Territory

PARSIPPANY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, October 29, 2020. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report Third Quarter 2020 Financial Results on Thursday October 29, 2020

Is (PCRX) Outperforming Other Medical Stocks This Year?

News for Pacira Pharmaceuticals Stock (PCRX)